MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors. 2019

Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14186 Stockholm, Sweden. shambhu.aralaguppe@gmail.com.

The detection of drug resistance mutations (DRMs) in minor viral populations is of potential clinical importance. However, sophisticated computational infrastructure and competence for analysis of high-throughput sequencing (HTS) data lack at most diagnostic laboratories. Thus, we have proposed a new pipeline, MiDRMpol, to quantify DRM from the HIV-1 pol region. The gag-vpu region of 87 plasma samples from HIV-infected individuals from three cohorts was amplified and sequenced by Illumina HiSeq2500. The sequence reads were adapter-trimmed, followed by analysis using in-house scripts. Samples from Swedish and Ethiopian cohorts were also sequenced by Sanger sequencing. The pipeline was validated against the online tool PASeq (Polymorphism Analysis by Sequencing). Based on an error rate of <1%, a value of >1% was set as reliable to consider a minor variant. Both pipelines detected the mutations in the dominant viral populations, while discrepancies were observed in minor viral populations. In five HIV-1 subtype C samples, minor mutations were detected at the <5% level by MiDRMpol but not by PASeq. MiDRMpol is a computationally as well as labor efficient bioinformatics pipeline for the detection of DRM from HTS data. It identifies minor viral populations (<20%) of DRMs. Our method can be incorporated into large-scale surveillance of HIV-1 DRM.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010802 Phylogeny The relationships of groups of organisms as reflected by their genetic makeup. Community Phylogenetics,Molecular Phylogenetics,Phylogenetic Analyses,Phylogenetic Analysis,Phylogenetic Clustering,Phylogenetic Comparative Analysis,Phylogenetic Comparative Methods,Phylogenetic Distance,Phylogenetic Generalized Least Squares,Phylogenetic Groups,Phylogenetic Incongruence,Phylogenetic Inference,Phylogenetic Networks,Phylogenetic Reconstruction,Phylogenetic Relatedness,Phylogenetic Relationships,Phylogenetic Signal,Phylogenetic Structure,Phylogenetic Tree,Phylogenetic Trees,Phylogenomics,Analyse, Phylogenetic,Analysis, Phylogenetic,Analysis, Phylogenetic Comparative,Clustering, Phylogenetic,Community Phylogenetic,Comparative Analysis, Phylogenetic,Comparative Method, Phylogenetic,Distance, Phylogenetic,Group, Phylogenetic,Incongruence, Phylogenetic,Inference, Phylogenetic,Method, Phylogenetic Comparative,Molecular Phylogenetic,Network, Phylogenetic,Phylogenetic Analyse,Phylogenetic Clusterings,Phylogenetic Comparative Analyses,Phylogenetic Comparative Method,Phylogenetic Distances,Phylogenetic Group,Phylogenetic Incongruences,Phylogenetic Inferences,Phylogenetic Network,Phylogenetic Reconstructions,Phylogenetic Relatednesses,Phylogenetic Relationship,Phylogenetic Signals,Phylogenetic Structures,Phylogenetic, Community,Phylogenetic, Molecular,Phylogenies,Phylogenomic,Reconstruction, Phylogenetic,Relatedness, Phylogenetic,Relationship, Phylogenetic,Signal, Phylogenetic,Structure, Phylogenetic,Tree, Phylogenetic
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015751 Genes, pol DNA sequences that form the coding region for retroviral enzymes including reverse transcriptase, protease, and endonuclease/integrase. "pol" is short for polymerase, the enzyme class of reverse transcriptase. pol Genes,pol Gene,Gene, pol
D059014 High-Throughput Nucleotide Sequencing Techniques of nucleotide sequence analysis that increase the range, complexity, sensitivity, and accuracy of results by greatly increasing the scale of operations and thus the number of nucleotides, and the number of copies of each nucleotide sequenced. The sequencing may be done by analysis of the synthesis or ligation products, hybridization to preexisting sequences, etc. High-Throughput Sequencing,Illumina Sequencing,Ion Proton Sequencing,Ion Torrent Sequencing,Next-Generation Sequencing,Deep Sequencing,High-Throughput DNA Sequencing,High-Throughput RNA Sequencing,Massively-Parallel Sequencing,Pyrosequencing,DNA Sequencing, High-Throughput,High Throughput DNA Sequencing,High Throughput Nucleotide Sequencing,High Throughput RNA Sequencing,High Throughput Sequencing,Massively Parallel Sequencing,Next Generation Sequencing,Nucleotide Sequencing, High-Throughput,RNA Sequencing, High-Throughput,Sequencing, Deep,Sequencing, High-Throughput,Sequencing, High-Throughput DNA,Sequencing, High-Throughput Nucleotide,Sequencing, High-Throughput RNA,Sequencing, Illumina,Sequencing, Ion Proton,Sequencing, Ion Torrent,Sequencing, Massively-Parallel,Sequencing, Next-Generation
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
January 2020, Frontiers in microbiology,
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
June 2021, Journal of medical virology,
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
January 2007, AIDS (London, England),
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
December 2010, Mini reviews in medicinal chemistry,
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
June 2022, Microbiology spectrum,
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
March 2014, AIDS (London, England),
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
January 2001, HIV sequence compendium,
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
December 2020, Nature communications,
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
July 2016, Journal of virology,
Shambhu G Aralaguppe, and Anoop T Ambikan, and Manickam Ashokkumar, and Milner M Kumar, and Luke Elizabeth Hanna, and Wondwossen Amogne, and Anders Sönnerborg, and Ujjwal Neogi
January 2013, Methods in molecular biology (Clifton, N.J.),
Copied contents to your clipboard!